<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:department>Basic Medical Sciences</gtr:department><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F325BF32-08AE-4621-8057-E5D6613B7308"><gtr:id>F325BF32-08AE-4621-8057-E5D6613B7308</gtr:id><gtr:name>St George's University of London</gtr:name><gtr:address><gtr:line1>Cranmer Terrace</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW17 0RE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C207B679-3105-4B7B-9092-60276D81E2E2"><gtr:id>C207B679-3105-4B7B-9092-60276D81E2E2</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>Greenwood</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9262858C-9703-4D11-BF26-7DD9FDB1D84E"><gtr:id>9262858C-9703-4D11-BF26-7DD9FDB1D84E</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Albert</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FJ007226%2F1"><gtr:id>FCF76552-F65C-40A0-9B48-80EF4C5D6183</gtr:id><gtr:title>Properties and function of TRPC proteins in vascular smooth muscle using transgenic mice</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J007226/1</gtr:grantReference><gtr:abstractText>The aim of our research is to discover molecules that control the diameter of blood vessels. These molecules will be future drug targets for prevention and treatment of cardiovascular disease (CVD).

A recent survey showed that CVD such as high blood pressure, heart attack, and stroke, cause 40% of all deaths in the UK. Also, CVD costs us over &amp;pound;29 billion a year in healthcare, and loss of productivity due to lost work days. With an aging population, these figures are likely to rapidly increase. In light of these facts, we need new drugs to prevent and treat VD. 

Not enough flow of blood causes cells to not receive enough nutrients (e.g. oxygen), and to build up more waste products (e.g. carbon dioxide), which leads to cells not working properly. CVD often leads to blood vessels contracting too much, which contributes to a reduction in blood flow. Therefore it is important to find out how blood vessels contract. We study muscle cells found in the walls of blood vessels, which important in making blood vessels contract.

It is known that calcium is an important molecule in making these muscle cells to contract. Our research investigates proteins, called TRPC channels, which are involved in increasing the concentration of calcium inside cells. TRPC channel proteins are pores which are found in the membrane that surrounds cells. Molecules cause these pores to open and close, which allows calcium to move into cells.

TRPC channels are important in controlling how blood vessel contract, and are believed to be involved in contributing to high blood pressure, which is a major risk factor for CVD. The present work will investigate members of the TRPC channel protein family, TRPC1 and TRPC5, in blood vessels from mice, which are an excellent model for understanding what happens in human blood vessels.

Our research we greatly advance knowledge on how blood vessel contract. This will ultimately help in the development of new treatments for CVD. It will also help understand ther diseases, which involve TRPC channels and changes in calcium levels inside cells.</gtr:abstractText><gtr:technicalSummary>Canonical transient receptor potential (TRPC) proteins are a family of non-selective Ca2+-permeable cation channels (TRPC1-C7) expressed in a plethora of cell types. TRPCs are activated by stimulation of G-protein-coupled and tyrosine kinase receptors, and form Ca2+ influx pathways involved in many cellular functions.

In native vascular smooth muscle cells (VSMCs), TRPCs are likely to be heteromeric structures composed of different TRPC subunits, which contribute to vascular disease by inducing excessive vasoconstriction and migration, growth and proliferation of VSMCs. TRPCs and associated signalling molecules are legitimate drug targets for prevention and treatment of cardiovascular diseases.

Studies on TRPCs have generally used anti-sense/small-interfering RNAs and dominant-negative technologies to 'knock-down' TRPCs in cultured VSMCs, and VSMC-derived cell lines. These studies have provided useful information on 'what can happen', but do not indicate 'what does happen' in native conditions - cultured cells and cell-lines have different cellular environments, and also may not express different TRPCs compared to native VSMCs. We address these issues by investigating single TRPC currents in acutely isolated VSMCs from TRPC transgenic mice. These approaches will reveal properties conferred by individual TRPCs in native vascular environments, and changes in TRPCs following knock-out of TRPC subunits.

Our hypothesis is that TRPC1/TRPC5 subunits confer distinct properties to TRPCs in native VSMCs; small channel conductance, stimulation by agents that deplete internal Ca2+ stores, dependence on protein kinase C (PKC) and phosphoinositols (PIs) for channel gating. We will compare TRPCs in TRPC1-/- and TRPC5-/- VSMCs as these channels are thought to form functional heteromeric TRPC1/C5 channel structures. Moreover, we intend to study the contribution of TRPC1 and TRPC5 proteins to alpha1-adrenoceptor-induced vasoconstrictions.</gtr:technicalSummary><gtr:potentialImpactText>In the UK, cardiovascular disease (CVD) accounts for 40% of all deaths. Moreover, CVD costs the country over &amp;pound;29bn, in healthcare costs (&amp;pound;16 bn) and loss of productivity (&amp;pound;13 bn). With inclusion of worldwide data, it is not surprising that cardiovascular research aimed at identifying new therapeutic targets represents multiple beneficiaries from academic, public and commercial environments. Our proposal will investigate such potential therapeutic targets, e.g. TRPC channel proteins and associated signalling molecules.

It should also be remembered that TRPC channels are expressed in many cell types, and are reported to have important physiological and pathological functions in an array of body systems. Therefore, TRPC channel proteins represent therapeutic targets for other diseases, which further increase the number of potential stakeholders supported by our research. 

Who will benefit from this research?
- Research groups in the UK/worldwide academic institutions involved in studying the molecular properties and function of TRP channels/Ca2+ signalling pathways in the cardiovascular system, and in other biomedical disciplines.

- Pharmaceutical companies involved in studying TRP channels/Ca2+ signalling pathways as potential therapeutic targets for development of treatments for diseases. For example, Novartis has published on the role of TRPC channels in respiratory diseases, Pfizer on TRPV1 channels in pain and cough reflexes, and GSK on TRPV4 and vascular/endothelin and bladder function.

- Providers of medical treatments, e.g. NHS and medical care insurance companies. CVD costs the UK about &amp;pound;16bn in healthcare.

- The public treasury. CVD costs the UK about &amp;pound;13bn in work productivity, resulting in a significant reduction in tax revenue. 

- The health of the population, both within and outside the UK.

How will they benefit from this research?
It is proposed that TRPC1 channel activity is linked to a range of physiological and pathological phenotypes majority of studies have been carried out using cultured cells or cell-lines, and little is known about the function of TRPC1 proteins in native tissues. Moreover, few studies have investigated the function of TRPC channels in TRPC1-/- mice, and no studies have investigated the molecular properties and function of TRPC channels in VSMCs from TRPC1-/- mice using single channel recording techniques. Consequently, stakeholders listed above will benefit from our proposal as,

- Our proposal will reveal new understanding and novel perspectives on the functioning of an important ion channel subunit involved in multiple cellular functions, which is studied in worldwide academic institutions and pharmaceutical companies.

- Understanding more about the molecular properties, activation mechanisms and functions of TRPC1 channels will identify new therapeutic targets - not only the channel proteins, but the associated signalling molecules involved in activating/regulating channel activity. This is likely to influence commercial concerns. As with all scientific discoveries, the timescale of these influences translating into therapeutics at the clinic is likely to be 10-15 years.

- TRPC1 has been implicated in a number of diseases, which have a significant impact on the mortality and morbidity of the population. In an aging population, the frequency of many of these chronic diseases, requiring long-term treatment, will not doubt increase. Development of new therapeutic targets and strategies are therefore essential for continued health of the population.

- An aging population with associated increases in chronic conditions are major financial implications for any society. New, more effective, treatments offering increased health benefits and better value for money are of obvious importance to governments.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>367567</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Role of P2X receptors in vascular smooth muscle</gtr:description><gtr:id>56F527E3-235B-4ABD-A7F5-F9E357719C7F</gtr:id><gtr:impact>2 papers</gtr:impact><gtr:outcomeId>544648ec9bbba2.98911177-1</gtr:outcomeId><gtr:partnerContribution>Provided research assistant collaboration</gtr:partnerContribution><gtr:piContribution>Provide technical support for wire myography experiments, helped write manuscripts</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Role on Orai1 proteins in vascular smooth muscle function</gtr:description><gtr:id>963CBC93-3155-4E41-9BBE-746EB55C1DD0</gtr:id><gtr:impact>Recent invited speaker at Young Life Scientists Symposium on 'Physiology and Pharmacology of TRP channels', King's College London, 4th October, 2014</gtr:impact><gtr:outcomeId>b95fe146b95fe15a-1</gtr:outcomeId><gtr:partnerContribution>Supplying Orai1 +/- mice, for production of orai1-/- genotypes</gtr:partnerContribution><gtr:piContribution>Collaboration with the Harvard Medical School to determine the role of Orai1 proteins in controlling vascular tone. This international and potentially very important collaboration is a direct result of support from my BBSRC grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St George's University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Role of PIP2 on TMEM16A ion channels</gtr:description><gtr:id>A04718E4-6613-4713-AE02-B78295A7F7A6</gtr:id><gtr:impact>2 papers, several abstracts</gtr:impact><gtr:outcomeId>54464730edf1e2.19957275-1</gtr:outcomeId><gtr:partnerContribution>Expression of TMEM16A in HEK293 cells</gtr:partnerContribution><gtr:piContribution>Development of common ideas, development of new techniques - expression of PIP2 sensors, dot-blots analysis to investigate ion channel/PIP2 interactions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Attendance at Research Day, St. George's, University of London, 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1969605C-710C-48E4-9591-446F120C4AF6</gtr:id><gtr:impact>Presented poster to academics, postgraduates, undergraduates (mainly MBBS, BSc Biomedical Sciences, MPharm students) from St. George's, University of London

No</gtr:impact><gtr:outcomeId>HryDEKSQS4b</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.researchday.sgul.ac.uk/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>136595</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigation into Calcium-sensing receptor mechanisms in the vasculature</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/13/10/30021</gtr:fundingRef><gtr:id>CBBF62C3-BAB6-4538-AA01-D74130D00E21</gtr:id><gtr:outcomeId>r-792788090.922672406a308f4</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>365834</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>STIM1-mediated PLC activity and TRPC1 channel activation in vascular smooth muscle</gtr:description><gtr:end>2018-06-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M018350/1</gtr:fundingRef><gtr:id>57D014B3-D622-4DA6-8304-23CB995CA7EF</gtr:id><gtr:outcomeId>56c1ec29b98979.83269704</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>114469</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Role of PIP2-binding protein MARCKS on voltage-gated Ca2+ channels and vascular contractility</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>FS/15/44/31570</gtr:fundingRef><gtr:id>BB8EBB95-65E8-4AF3-ADC0-861EAB288290</gtr:id><gtr:outcomeId>56c6da2b782722.16140523</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>It is hoped that our data will impact societies understanding of vascular physiology and pathology. This will lead to better treatments for cardiovascular disease, improved population morbidity and reduce mortality. Furthermore it will have a positive impact of economic prosperity of the population.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>8CE727BE-5949-40B9-B5AE-74DD306EBDD9</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5446722469c1d0.69716658</gtr:outcomeId><gtr:sector>Chemicals,Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Calcium is very important for controlling how our cells work. We have found a new way that calcium can be transported into our cells. We believe that this transport pathway is important for controlling how our blood vessels become constricted, which is what happens when we have high blood pressure. In the future we may be able to block this new calcium transport pathway to treat high blood pressure.</gtr:description><gtr:exploitationPathways>Our data provide the strongest evidence so far that TRPC1 proteins form store-operated channels, and that these channels have a novel activation pathway involving PIP2, PKC, and MARCKS. We have also made the fundamental discovery that store-depletion is coupled to this TRPC1 channel activation process through STIM1 inducing PLC activity - this a novel and potentially high impact finding. We therefore believe that our results make a significant contribution to understanding TRP channel function in vascular smooth muscle and other cell types, which will be important for other areas of investigation by many different research groups.</gtr:exploitationPathways><gtr:id>5369E7FE-9900-4C9F-8FA9-BAE8AC384067</gtr:id><gtr:outcomeId>54466f992a72e6.90408339</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Use of lentiviral technology to transfect shRNA sequences into vascular smooth muscle cells</gtr:description><gtr:id>C9A8ED97-1AF3-4888-991D-5116149CC712</gtr:id><gtr:impact>This has enabled us to carry out molecular interventions for the first time in out laboratory</gtr:impact><gtr:outcomeId>544668c4b86b99.87276793</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Lentiviral shRNA techniques</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GFP-PLCdelta-PH is a plasmid used to detect PIP2/IP3 levels</gtr:description><gtr:id>6A5F174C-35AA-423C-A2B6-9F8A52F1477A</gtr:id><gtr:impact>The use of GFP-PLCdelta-PH has enabled us to measure PLC activity in primary cultured vascular smooth muscle cells. This techniques had a major impact in our recent work showing that store-depletion induces PLC activity</gtr:impact><gtr:outcomeId>5446675d6af0e9.79735465</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PIP2 sensor</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed a cell culture techniques whereby vascular smooth muscle cells are maintained in low (1%) serum conditions for up to 7 days. These cells retain their contractile properties</gtr:description><gtr:id>CA6AD0E8-4D32-490D-A0DB-DE84F041F32E</gtr:id><gtr:impact>The development of these cell culture conditions has enabled us to carry out molecular interventions (transfection of plasmids, siRNA, biosensors etc.) on vascular smooth muscle cells with a contractile phenotype</gtr:impact><gtr:outcomeId>54466857f0d482.93013485</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Primary cell culture</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>594B52B8-575D-468F-BDA6-771B5324C0B9</gtr:id><gtr:title>ATP-evoked sustained vasoconstrictions mediated by heteromeric P2X1/4 receptors in cerebral arteries.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b054e39b59b72904d0d77370e598999d"><gtr:id>b054e39b59b72904d0d77370e598999d</gtr:id><gtr:otherNames>Harhun MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>5446653a67a6f8.41091316</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FAB7AE5D-6667-4D76-9ADC-44061A2A2470</gtr:id><gtr:title>Stimulation of store-operated canonical transient receptor potential 1 channels requires Gq-protein, Phospholipase C, and stromal interaction molecule in vascular smooth muscle</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>54464a0401fab3.80414810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B30CC180-81DF-4518-80A0-ADB1D730F5DE</gtr:id><gtr:title>Store-operated interactions between plasmalemmal STIM1 and TRPC1 proteins stimulate PLC?1 to induce TRPC1 channel activation in vascular smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>58984533d37649.26340914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD0B99F9-91E0-4A32-AA26-9B47C69D1EFE</gtr:id><gtr:title>Store depletion induces G&amp;Icirc;&amp;plusmn;q-mediated PLC&amp;Icirc;&amp;sup2;1 activity to stimulate TRPC1 channels in vascular smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>56c1e023870080.66596686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>96117421-678F-4690-90E6-5D2F7D4B6472</gtr:id><gtr:title>TRPC1 proteins confer PKC and phosphoinositol activation on native heteromeric TRPC1/C5 channels in vascular smooth muscle: comparative study of wild-type and TRPC1-/- mice.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>5446653b606406.50634201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8F2495F-F5B5-4039-86FC-9F05576D0DEC</gtr:id><gtr:title>Potent vasorelaxant activity of the TMEM16A inhibitor T16A(inh) -A01.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/592deba7313c885fa759da59692247f6"><gtr:id>592deba7313c885fa759da59692247f6</gtr:id><gtr:otherNames>Davis AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5446653b2fdc43.66697313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B3C55B2-1BCE-423E-A14C-883D862A3156</gtr:id><gtr:title>The regulation of Ca2+-activated chloride channels by cholesterol and phophatidylinositol 4,5-bisphosphate in rat pulmonary artery</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b4fee4fe6f36be618dd10055565633"><gtr:id>f9b4fee4fe6f36be618dd10055565633</gtr:id><gtr:otherNames>Pritchard HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5446642120ac46.48891834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27F30160-047B-4264-92CB-ECB4BDE14A8A</gtr:id><gtr:title>Vascular smooth muscle cells from small human omental arteries express P2X1 and P2X4 receptor subunits.</gtr:title><gtr:parentPublicationTitle>Purinergic signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8c9455161f3f7c47709ee810b7e4374"><gtr:id>b8c9455161f3f7c47709ee810b7e4374</gtr:id><gtr:otherNames>Nichols CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1573-9538</gtr:issn><gtr:outcomeId>5446653a9a99c4.60103721</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64AC9235-832F-40C9-9532-A275AA60C47B</gtr:id><gtr:title>Stimulation of store-operated canonical transient receptor potential 1 channels requires Gq-protein, phospholipase C, and stromal interaction molecule 1 in vascular smooth muscle</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56c1e4b89cda67.27687224</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53C9F636-0F73-4161-A2D1-91604563BC46</gtr:id><gtr:title>Heteromeric TRPV4/TRPC1 channels mediate calcium-sensing receptor-induced nitric oxide production and vasorelaxation in rabbit mesenteric arteries.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1e80f35586d11c8f8971d3de69d3acb"><gtr:id>b1e80f35586d11c8f8971d3de69d3acb</gtr:id><gtr:otherNames>Greenberg HZE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>5a350266ca5478.45216460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>520054B7-733C-4BB8-85C6-8A5EB22B59ED</gtr:id><gtr:title>Evidence that Orai1 does not contribute to store-operated TRPC1 channels in vascular smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>Channels (Austin, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1933-6950</gtr:issn><gtr:outcomeId>5a351349484092.02756661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CDA0DA8-A735-40C3-B679-DB3B4E1067EB</gtr:id><gtr:title>Myristoylated alanine-rich C kinase substrate (MARCKS) mediates activation of canonical transient receptor potential1 (TRPC1) channels in vascular myocytes</gtr:title><gtr:parentPublicationTitle>Proc 37th IUPS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>54466310461c70.95636669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC827445-F580-4077-9673-C19A1779D303</gtr:id><gtr:title>Stimulation of calcium-sensing receptors induces endothelium-dependent vasorelaxations via nitric oxide production and activation of IKCa channels.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389032400c5fd1d2fe284235667465d7"><gtr:id>389032400c5fd1d2fe284235667465d7</gtr:id><gtr:otherNames>Greenberg HZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn><gtr:outcomeId>56c1b3c4d1e9a3.70591447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A9FDEC9-A312-4EEA-A2D7-9D8624116CD0</gtr:id><gtr:title>Myristoylated alanine-rich C kinase substrate coordinates native TRPC1 channel activation by phosphatidylinositol 4,5-bisphosphate and protein kinase C in vascular smooth muscle.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>5446653af2c959.83167966</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D895894-BA7B-4D1C-B658-BAC74865C981</gtr:id><gtr:title>The calcilytics Calhex-231 and NPS 2143 and the calcimimetic Calindol reduce vascular reactivity via inhibition of voltage-gated Cachannels.</gtr:title><gtr:parentPublicationTitle>European journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1e80f35586d11c8f8971d3de69d3acb"><gtr:id>b1e80f35586d11c8f8971d3de69d3acb</gtr:id><gtr:otherNames>Greenberg HZE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-2999</gtr:issn><gtr:outcomeId>585d3524ec8205.50597041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A89CA1D-FC31-43A9-A649-D68857E4624F</gtr:id><gtr:title>Inhibitory Role of PIP2 on Calcium-Activated Chloride Channel Activity</gtr:title><gtr:parentPublicationTitle>Biophysical Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6f40cc104c63660020823e7f3308fa2"><gtr:id>d6f40cc104c63660020823e7f3308fa2</gtr:id><gtr:otherNames>Pritchard H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5446660f2881c6.98313539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF84DA31-081E-4B3F-AED7-1BD274BA2229</gtr:id><gtr:title>Inhibitory role of phosphatidylinositol 4,5-bisphosphate on TMEM16A-encoded calcium-activated chloride channels in rat pulmonary artery.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db4c27dcc69e871c935a4ca0a4ca9f67"><gtr:id>db4c27dcc69e871c935a4ca0a4ca9f67</gtr:id><gtr:otherNames>Pritchard HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5446653ac9bb83.94580554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA6E4EF1-8F1A-4D4E-BDDF-948073D593D8</gtr:id><gtr:title>Functional role of CFTR in rat mesenteric artery</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b4fee4fe6f36be618dd10055565633"><gtr:id>f9b4fee4fe6f36be618dd10055565633</gtr:id><gtr:otherNames>Pritchard HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544662318172b5.08713379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79B35AAC-849C-48C5-B080-4DB14DA27837</gtr:id><gtr:title>Cholesterol depletion reveals an inhibitory role of PIP2 on Ca2+-activated Cl- channel activity in rat pulmonary arteries</gtr:title><gtr:parentPublicationTitle>Proc 37th IUPS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9b4fee4fe6f36be618dd10055565633"><gtr:id>f9b4fee4fe6f36be618dd10055565633</gtr:id><gtr:otherNames>Pritchard HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>5446639aeb7366.41959326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDF16716-0F4C-458D-BF4F-B1EA2367CE93</gtr:id><gtr:title>MARCKS modulates vascular contractility by increasing voltage-gated Ca2+ currents</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c435e1e2d848d52679ac71e2f5afee1"><gtr:id>2c435e1e2d848d52679ac71e2f5afee1</gtr:id><gtr:otherNames>Jahan KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c1e1feb32709.78046560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7B6008C-5C6C-4835-B626-F2C995B907FE</gtr:id><gtr:title>Store-depletion activates Galphaq-PLC activity through a STIM1/TRPC1-mediated but Orai1-independent mechanism in vascular smooth muscle cells</gtr:title><gtr:parentPublicationTitle>Proc Physiol Soc</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7458cbd28d9ec922eeac79922201ea5"><gtr:id>c7458cbd28d9ec922eeac79922201ea5</gtr:id><gtr:otherNames>Shi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c1e2b9559396.79684975</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J007226/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>A442BF36-F335-483E-9282-F3BB48AC2C47</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Cell biology</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>9BDF80E2-029E-4505-B7EE-DB0FA633E483</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Omic sciences &amp; technologies</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>D22AE401-1C35-4706-A19C-10861ABC82CD</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biological membranes</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>73EF98E1-3FA8-46A0-BE46-00AE16C7D999</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Communication &amp; signalling</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>FEBB49F4-3228-4CBC-98AB-99A078FB98B5</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Functional genomics</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>